Actos (Pioglitazone) Cost in Alaska 2026: Prices, Insurance, and Savings

What Does Pioglitazone Actually Cost in Alaska?

Generic pioglitazone averages about $15 per month across Alaska retail pharmacies in 2026, making it one of the least expensive branded-class diabetes medications on the market. The Takeda brand-name version, Actos, carries a list price near $60 per month, though very few patients pay that figure after insurance or discount adjustments.

Pricing varies by pharmacy location and chain. Anchorage, Fairbanks, and Juneau tend to cluster near the $15 average, but smaller rural pharmacies with higher overhead may charge $20 to $25. Big-box and mail-order pharmacies consistently price at or below the state average. A 90-day mail-order fill often costs less than three separate 30-day retail fills due to reduced dispensing fees.

For context, pioglitazone lost patent exclusivity in 2012, and multiple generic manufacturers now compete in the market. That competition is the primary driver behind a cash price that has dropped roughly 75% from the original brand cost. The FDA Orange Book lists more than a dozen approved generic pioglitazone products rated as therapeutically equivalent to Actos.

Compared to newer diabetes drug classes, pioglitazone is a fraction of the cost. GLP-1 receptor agonists like semaglutide (Ozempic) carry list prices above $900 per month, and SGLT2 inhibitors range from $400 to $550 before insurance. Pioglitazone at $15 per month represents a 97% cost reduction relative to those alternatives, a factor that the American Diabetes Association Standards of Care explicitly names when recommending treatment selection for patients with cost barriers [1].

Alaska Medicaid: Why Actos Is Not Covered and What to Do

Alaska Medicaid does not include Actos or generic pioglitazone on its preferred drug list as of 2026. This means beneficiaries cannot fill pioglitazone prescriptions through Medicaid without pursuing a prior authorization exception, and even those requests are frequently denied.

The exclusion likely reflects formulary committee decisions favoring metformin, sulfonylureas, and select SGLT2 inhibitors as preferred agents. Alaska's Medicaid pharmacy program follows a preferred drug list managed by the state's Department of Health, and thiazolidinediones (the drug class that includes pioglitazone) have been deprioritized on most state Medicaid formularies nationwide over the past decade.

Patients on Alaska Medicaid who need pioglitazone have several paths forward. First, prescribers can submit a prior authorization request documenting clinical necessity, particularly if metformin is contraindicated or not tolerated. Second, the $15 cash price means many patients can afford to pay out of pocket without insurance. Third, some manufacturer and pharmacy discount programs reduce the cost to $0 to $10 per month. The Endocrine Society Clinical Practice Guideline on type 2 diabetes pharmacotherapy supports pioglitazone as a second-line agent when insulin sensitization is the treatment goal, which can strengthen a prior authorization appeal [2].

Alaska Medicaid beneficiaries should also ask about the state's 340B program, which provides discounted medications through qualifying health centers. Several federally qualified health centers in Alaska participate in 340B pricing, and pioglitazone acquired through this channel can cost under $5 per month.

Insurance Coverage Across Alaska Plans

Most commercial insurance plans and Medicare Part D formularies in Alaska cover generic pioglitazone, typically on Tier 1 or Tier 2. That translates to copays between $0 and $15 per fill for most enrollees.

Premera Blue Cross Blue Shield of Alaska, the state's dominant commercial insurer, lists generic pioglitazone on its preferred generic tier. Moda Health, Aetna plans available through the federal marketplace, and employer-sponsored plans through large carriers follow the same pattern. Brand-name Actos, by contrast, often sits on a non-preferred brand tier with $40 to $60 copays, making the generic the obvious choice.

Medicare Part D plans in Alaska almost universally cover pioglitazone. The Centers for Medicare & Medicaid Services formulary finder tool allows beneficiaries to search their specific plan. Under the Part D redesign that took effect in 2025, annual out-of-pocket costs are capped at $2,000. Given pioglitazone's low cost, most Part D enrollees never approach that cap from this medication alone.

For patients with high-deductible health plans (HDHPs), the cash-pay price of $15 often falls below or near the negotiated insurance rate, meaning paying cash with a discount card may actually cost less than running the prescription through insurance during the deductible phase. Pharmacists in Alaska can process a GoodRx, RxSaver, or SingleCare coupon at the register even if the patient has active insurance.

The ADA's 2024 Standards of Care state: "Cost and access to medications are important considerations and should factor into the choice of glucose-lowering therapy" [1]. Pioglitazone's price profile makes it one of the most accessible diabetes medications regardless of insurance status.

Compounded Pioglitazone: Legal in Alaska via 503A Pharmacies

Compounded pioglitazone is legal in Alaska through licensed 503A compounding pharmacies. These pharmacies can prepare pioglitazone in custom dosage forms or strengths based on a patient-specific prescription.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications for individual patients when a prescriber determines a medical need, such as allergy to an inactive ingredient in the commercial tablet, need for a liquid formulation, or requirement for a non-standard dose. The FDA's compounding policy page outlines these requirements [3].

In practical terms, few Alaska patients need compounded pioglitazone. The commercial generic is inexpensive, comes in three strengths (15 mg, 30 mg, 45 mg), and is widely stocked. Compounding becomes relevant mainly for patients who cannot swallow tablets or who need a dye-free preparation due to allergies. Some 503A pharmacies list compounded pioglitazone suspensions at $0 to $10 per month, competitive with or below the generic tablet price.

Alaska does not impose additional state-level restrictions on 503A compounding beyond federal requirements. The Alaska Board of Pharmacy requires compounding pharmacies to hold a valid state license and comply with USP standards for non-sterile compounding.

Telehealth Access to Pioglitazone in Alaska

Alaska permits telehealth prescribing of pioglitazone with no geographic or modality restrictions. A provider licensed in Alaska can evaluate a patient via video or audio visit and prescribe pioglitazone without an in-person exam.

This matters in Alaska more than almost any other state. Over 40% of Alaska's population lives outside the Anchorage metro area, and many communities are accessible only by air or water. The Alaska State Medical Board adopted permanent telehealth-friendly prescribing rules following the pandemic-era expansions. Pioglitazone, as a non-controlled oral medication, faces no additional prescribing barriers via telehealth.

HealthRX and similar telehealth platforms can prescribe pioglitazone to Alaska residents after a clinical evaluation. The prescription can be sent electronically to any Alaska retail or mail-order pharmacy. Patients in remote areas like Bethel, Nome, or Kodiak can access the same medication at comparable prices to Anchorage residents when using mail-order fulfillment.

The CDC's National Diabetes Statistics Report estimates that 9.6% of Alaska adults have diagnosed diabetes, with significant disparities in rural and Alaska Native communities [4]. Telehealth closes a real access gap for these populations.

When Pioglitazone Makes Clinical Sense: Evidence and Off-Label Uses

Pioglitazone is FDA-approved as an adjunct to diet and exercise for type 2 diabetes mellitus. It works by activating PPAR-gamma receptors, which improves insulin sensitivity in muscle, fat, and liver tissue. The Actos prescribing label provides full approved indication details [5].

Beyond glycemic control, pioglitazone has the strongest randomized trial evidence of any drug for nonalcoholic steatohepatitis (NASH), now termed metabolic dysfunction-associated steatohepatitis (MASH). The PIVENS trial (N=247), published in the New England Journal of Medicine in 2010, randomized non-diabetic adults with biopsy-confirmed NASH to pioglitazone 30 mg, vitamin E 800 IU, or placebo for 96 weeks. Pioglitazone produced histologic improvement in 34% of patients compared to 19% on placebo, with significant reductions in hepatic steatosis, lobular inflammation, and insulin resistance [6].

Dr. Arun Sanyal, the PIVENS principal investigator, noted at the time: "Pioglitazone produced meaningful histologic improvement in NASH, including resolution of steatohepatitis in a subset of patients." The AASLD practice guidance on NAFLD lists pioglitazone as a treatment option for biopsy-proven NASH in patients with or without type 2 diabetes [7].

Pioglitazone also demonstrated cardiovascular benefit in the PROactive trial (N=5,238), which showed a 16% reduction in the composite of all-cause mortality, non-fatal myocardial infarction, and stroke in patients with type 2 diabetes and macrovascular disease over 34.5 months of follow-up [8]. The AHA/ACC guidelines acknowledge this cardiovascular signal, though they stop short of recommending pioglitazone specifically for cardioprotection when SGLT2 inhibitors and GLP-1 agonists have stronger outcome data [9].

Known risks include weight gain (typically 2 to 4 kg), fluid retention, and a small increased risk of bone fractures, particularly in postmenopausal women. The FDA label includes a boxed warning regarding congestive heart failure. These risks must be weighed against the drug's benefits, especially its low cost and unique mechanism.

How to Get the Cheapest Pioglitazone in Alaska

The lowest-cost path depends on your insurance status. Here is a practical breakdown.

Uninsured or high-deductible plan: Use a free discount card (GoodRx, RxSaver, or SingleCare) at any Alaska retail pharmacy. Expect to pay $8 to $18 for a 30-day supply of generic pioglitazone 30 mg. Costco and Walmart pharmacies in Anchorage and Fairbanks consistently price at the low end. You do not need a Costco membership to use the pharmacy.

Commercial insurance: Fill the generic at your plan's preferred pharmacy. Copays range from $0 to $15. If your plan uses a mail-order benefit, a 90-day fill may carry a single copay.

Medicare Part D: Fill at a preferred network pharmacy for the lowest copay, typically $0 to $10. Check your plan's formulary tier using the Medicare Plan Finder.

Alaska Medicaid: As noted above, pioglitazone is not covered. Pay cash with a discount card ($8 to $18) or ask your provider about a prior authorization exception.

Manufacturer savings: Takeda, the original Actos manufacturer, previously offered a savings card, but brand-name Actos savings programs have largely been discontinued as the generic market matured. No active Takeda-sponsored patient assistance program exists for pioglitazone as of 2026.

340B pricing: If you receive care at a federally qualified health center (FQHC), community health center, or tribal health organization in Alaska, ask about 340B drug pricing. The Alaska Native Tribal Health Consortium and Southcentral Foundation participate in 340B, and pioglitazone through these programs can cost $0 to $5 per fill.

The ADA's position statement on insulin affordability and diabetes drug costs emphasizes that providers should actively help patients identify the lowest-cost option for each prescribed medication [1].

Pioglitazone Dosing and What to Expect

Standard starting dose is 15 mg or 30 mg once daily, taken with or without food. The maximum approved dose is 45 mg daily. Most prescribers start at 15 mg and titrate up after 8 to 12 weeks based on HbA1c response and tolerability.

Full glycemic effect takes 8 to 12 weeks to manifest, reflecting pioglitazone's mechanism of altering gene transcription in adipose and hepatic tissue rather than directly stimulating insulin secretion. Patients should not expect immediate blood sugar changes comparable to sulfonylureas or insulin.

Monitoring includes baseline and periodic liver function tests (ALT), though the risk of hepatotoxicity is far lower than with troglitazone, the withdrawn first-generation thiazolidinedione. Watch for peripheral edema and unexplained weight gain, which may signal fluid retention. Report any shortness of breath or rapid weight gain to your prescriber immediately.

A fasting lipid panel at baseline and 3 to 6 months is reasonable, as pioglitazone modestly increases HDL and may increase LDL. The typical HDL increase is 3 to 5 mg/dL based on PROactive trial data [8].

For patients using pioglitazone off-label for NASH/MASH, the standard studied dose in PIVENS was 30 mg daily for 96 weeks [6]. Prescribers monitoring NASH treatment response may order repeat imaging (MRI-PDFF or FibroScan) at 6 to 12 months.